熱門資訊> 正文
德尼凡斯塔在后期试验中成功后，萨吉梅特崛起
2025-10-24 21:37
- Sagimet Biosciences (NASDAQ:SGMT) announced positive results from a late-stage trial of denifanstat, a treatment for moderate to severe acne vulgaris, which was conducted by its partner, Ascletis Bioscience, in China.
- The trial successfully achieved all primary and secondary objectives.
- At the 12-week mark, patients treated with denifanstat experienced treatment success rates that were more than double those of the placebo group, showing significant improvements in both inflammatory and non-inflammatory acne lesions.
- Overall, denifanstat was well tolerated by participants. Following the announcement, SGMT stock rose approximately 6.3%.
More on Sagimet Biosciences
- Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts
- Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript
- Sagimet Biosciences: Strong Denifanstat Pipeline Progress, Funding Overhang Keeps Stock At Hold
- Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
- MASH drug developers rise as FDA accepts lenient trial requirement
推薦文章
華盛早報 | 達成共識！貝森特「不再考慮」對中國加徵100%關税，美股三大股指期貨齊漲！賽力斯今起招股
一周財經日曆 |下周重磅事件搶先看：美聯儲利率決議、科技巨頭財報密集來襲
港股周報 | 利好不斷！恆指重回26000點；高息股獲資金青睞！農業銀行錄得12連漲
一周IPO | 八馬茶業、滴普科技預計下周二上市；傳賽力斯最快下周一招股
美股機會日報 | 9月CPI低於預期！三大股指期貨直線拉昇；英特爾盤前大漲超5%
營收創新高、利潤暴跌29%！馬斯克的AI豪賭能撐起特斯拉的未來嗎？
甲骨文兩日跌超10%，「超預期宏偉目標」不再「吃香」？
小馬智行、文遠知行回港上市，迎Robotaxi 的deepseek時刻？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
